D039: EMT specific splicing mediates ferroptosis sensitivity

FAU own research funding: EFI / IZKF / EAM ...


Start date : 01.07.2023

End date : 31.12.2025

Project details

Scientific Abstract

We have demonstrated that the EMT-activator ZEB1 provides cancer cells not only with aberrant motility, but also with survival traits enabling tumor progression, metastasis and drug resistance. Our aim is to eliminate these aggressive ‘untargetable’ EMT-state cancer cells, which strikingly show a high sensitivity to ferroptotic cell death. In this project, we want to elucidate the molecular basis of ZEB1 – associated ferroptosis sensitivity to exploit it as a novel therapeutic target.

Involved:

Simone Brabletz Project Leader Arndt Hartmann Project Member Felix Engel Project Member

Contributing FAU Organisations:

Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Lehrstuhl für Experimentelle Medizin II (Molekulare Tumorforschung) (EXP2MED) Professur für Experimentelle Nieren- und Kreislaufforschung Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Medizinische Fakultät

Research Areas

Microscope SVG Advanced Projects Field of Research